ArticleOphthalmology science2026
Small Extracellular Vesicle-Mediated Peptide Delivery to the Mouse Corneal Endothelium In Vivo.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular Vesicles for Corneal Endothelial Repair.International journal of molecular sciences · 2026Review
- Metabolic and redox adaptations of the corneal endothelium: From metabolic plasticity to therapeutic opportunities.Redox biology · 2026Review
Corrections and comments
- Erratum issuedErrata.2026
Authors and funding
4 authors.
Funding
Abstract
Purpose: To investigate the utility of human corneal endothelial cell (hCEC)-derived small extracellular vesicles (sEVs) as a delivery system to the mouse corneal endothelium (CE) in vivo. Design: Laboratory study. Subjects: C57BL/6 mice. Methods: hCEC-derived sEV were isolated from culture media using differential ultracentrifugation. Size, number, and morphology were characterized using nanoparticle tracking analysis and transmission electron microscopy (TEM). sEV markers were confirmed using an sEV detection antibody panel. PKH26-labeled sEV were injected into the anterior chamber of wild-type mice, and corneal endothelial uptake of sEV was assessed by colocalization of 4',6-diamidino-2-phenylindole and PKH26 fluorescence on corneal whole mounts. Saponin permeabilization and sonication were used to load FITC-conjugated peptide into sEV. Delivery to mouse CE in vivo following intracameral injection was assessed by colocalization analysis of PKH26-labeled sEV with FITC-conjugated peptide. An average of 5 × 10 Main Outcome Measures: sEV-mediated endothelial targeting. Results: Morphology and size of sEVs were confirmed by TEM, and the presence of sEV markers, flotillin-1, ICAM, programmed cell death 6 interacting protein (ALIX), immunoglobulin superfamily member 8 (CD81), lysosome-associated membrane protein 3 (CD63), annexin A5, and tumor susceptibility gene 101 (TSG101), was confirmed by immunoblotting. Confocal microscopy of whole-mounted mouse corneas, performed 2 days after intracameral injection of PKH26-labeled sEVs containing FITC-conjugated peptide, showed localization of sEVs within the CE. Colocalization of PKH26 and FITC signals in the mouse CE confirmed delivery of the peptide cargo via hCEC-derived sEVs in the mouse CE in vivo. Conclusions: We demonstrate proof of principle of using hCEC-derived sEVs for delivery of potential therapeutic agents to the mouse CE in vivo via intracameral injection. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.